Navigation Links
Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Date:9/18/2012

LEXINGTON, Mass., Sept. 18, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the company was awarded U.S. Patent 8,268,971, entitled "Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity."

The patent covers milk derived antibody compositions that specifically target and modulate an apical intestinal receptor and which are formulated for direct delivery to the gastrointestinal tract of a patient.  The patent also covers treatment of diabetes or obesity by using these antibodies to modulate a sugar receptor.  The types of intestinal receptors disclosed in the patent are very broad, and include sugar transporters, ion channels, sensors, and bile acid transporters.

"This patent highlights the broad applicability of our AVX Oral Antibody technology platform," stated Barbara Fox, PhD, CEO of Avaxia.  "Our oral antibodies can address membrane bound targets as well as soluble targets such as TNF for inflammatory bowel disease and radiation induced damage to the mouth and intestines.  Membrane bound targets such as sugar transporters have been implicated in diabetes and obesity, which are very attractive markets for our oral antibodies."

About Avaxia Biologics:

Avaxia is developing orally administered antibody therapeutics that act locally within the digestive tract.  Antibodies are widely used as therapeutics, with nearly $50 billion in annual sales worldwide.  Ordinary antibodies are injected or infused rather than administered orally because they are destroyed in the digestive tract.  In contrast, we have developed proprietary antibodies that resist digestion.  Our lead product is an oral antibody against tumor necrosis factor (TNF) for inflammatory bowel disease (IBD).  Existing anti-TNF drugs have proven effective for IBD but have serious immunosuppression side effects because they affect the entire body, not just the gastrointestinal (GI) tract where the inflammation occurs.  The goal of our IBD program is to deliver our anti-TNF antibody locally in the GI tract to minimize side effects from systemic drug exposure.  Avaxia also has programs in GI acute radiation syndrome, celiac disease, oral mucositis, diabetes, and obesity.


'/>"/>
SOURCE Avaxia Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
2. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
3. South and Central America Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
4. CMC Biologics Establishes Commercial Presence in Japan through Strategic Agreement with Innomedica
5. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
6. CMC Biologics Announces Mark W. Sawicki as Vice President, Global Business Development
7. Brazil Orthopedic Devices Market Outlook to 2018 - Arthroscopy, Cranio Maxillofacial Fixation (CMF), Hip Reconstruction, Knee Reconstruction, Spinal Surgery, Orthobiologics, Trauma Fixation and Others
8. WuXi PharmaTech to Manufacture Ibalizumab for TaiMed Biologics
9. Synthetic Biologics Reports Second Quarter 2012 Financial Results
10. Global Spinal Devices and Biologics Market 2011-2015
11. CMC Biologics Acquires XOMAs Bay Area Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
Breaking Medicine News(10 mins):